LBA1Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC D R Gandara, M Reck,S Morris,A Cardona,D Mendus,M Ballinger,A RittmeyerANNALS OF ONCOLOGY（2018）引用 20|浏览79暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
